|
Toshiba Medical Announces Study on Use of 64-Slice CT Angiography in the Early Diagnosis and Treatment of Coronary Artery Disease in Diabetics
|
 |
November 6, 2007 -- TUSTIN, Calif. --
Toshiba America Medical Systems, Inc. today announced
faCTor64,
the Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk
Diabetic Patients Using CT Angiography, Following CorE 64: A Randomized Control
Study. Toshiba's CorE 64 (Coronary Evaluation on 64) study is taking place across
seven countries comparing the use of CT as the primary diagnostic tool for detecting
cardiovascular diseases and disorders, as compared to cardiac catheterization.
It is estimated that approximately 16-million Americans have coronary heart disease
(CHD) of which 500,000 die annually. Most people with CHD have no symptoms and
about 300,000 per year have their first presentation of CHD as either heart attack
or sudden death. Nonetheless, there is no accepted detection test for the presence
of CHD, as there is for breast cancer or colon cancer. faCTor64 is a landmark
study to assess an asymptomatic diabetic population at higher risk for CHD using
a revolutionary modality, cardiac CT angiography.
"Patients with
diabetes have two to four times greater risk
of cardiovascular
disease than non-diabetic patients"
Donald
Lappe, MD, FACC
|
|
|
The study will be performed in conjunction with Intermountain Healthcare, a community-owned
system of nonprofit hospitals and clinics based in Salt Lake City, Utah that
provides medical care to residents of Utah and Idaho. More than 1,000 patients
from Utah, women older than 55 years old and men older than 50 years old, will
be enrolled in the faCTor64 study using Intermountain Healthcare's diabetes registry
of 30,000 patients, who have already received best-practice diabetic care. Intermountain,
known for its quality initiatives, has one of the largest diabetic databases
in the country.
The faCTor64 study will use Toshiba's Aquilion 64-slice CT system
to capture obstructive and non-obstructive, or sub-clinical, coronary heart disease
data to determine the best way to treat diabetic patients.
"Patients with diabetes have two- to four-times greater risk of cardiovascular disease than non-diabetic patients," explained Dr. Donald Lappe, FACC, chief of cardiology at Intermountain Medical Center in Salt Lake City and medical director of the Intermountain Healthcare Cardiovascular Clinical Program. "This,
coupled with the fact that cardiovascular death is the most common cause of mortality
among Type 2 diabetics, emphasizes the importance of the faCTor64 study.
The ability to detect CHD in at-risk, asymptomatic patients will have a significant
impact on the ability to improve their cardiac conditions and will help save
lives."
"We believe the results of faCTor64 will improve the diagnosis and
treatment of diabetes patients, who are more likely to develop CHD," said Toshihiro Rifu, senior fellow, Toshiba Medical Systems Corporation. "This
study will provide optimal information to guide patient management and measure
clinical outcomes."
The faCTor64 procedure is based on Toshiba's CorE 64 study and will be conducted
in partnership with Johns Hopkins University. Enrollment for the study has already
begun. Intermountain Healthcare Center is using its five Toshiba Aquilion 64-slice
CT systems to diagnose patients in the study.
About Toshiba
With headquarters in Tustin, Calif., Toshiba America Medical Systems markets,
sells, distributes and services diagnostic imaging systems, and coordinates clinical
diagnostic imaging research for all modalities in the United States. Toshiba
Medical Systems Corp., an independent group company of Toshiba Corp., is a global
leading provider of diagnostic medical imaging systems and comprehensive medical
solutions, such as CT, Cath & EP Labs, X-ray, Ultrasound, Nuclear Medicine, MRI
and information systems. Toshiba Corp. is a leader in information and communications
systems, electronic components, consumer products, and power systems. Toshiba
has approximately 191,000 employees worldwide and annual sales of $60 billion.
For more information, visit www.medical.toshiba.com.
Aquilion is a trademark of Toshiba Medical Systems Corporation.
Source: Toshiba
America Medical Systems
|
